publications-banner
Information about pipeline products
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
PublicationView
HER3-DXd
Current and emerging treatment options for patients with metastatic EGFR-mutated non-small cell lung cancer after progression on osimertinib and platinum-based chemotherapy: A podcast discussion
T-DXd
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan
HER3-DXd
EGFR mutations are not all the same: The importance of biomarker testing in non-small cell lung cancer (NSCLC)—a podcast discussion between patients and oncologists
Edoxaban
Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: The ETNA-AF-Europe registry
Valemetostat
Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects
Edoxaban
Predictive factors and clinical events associated with edoxaban interruption and heparin bridging strategy: EMIT-AF/VTE
T-DXd
Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial
HER3-DXd
HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy
Edoxaban
Incidence and risk factors for venous thromboembolism in the Cancer-VTE registry pancreatic cancer subcohort
HER3-DXd
Treatment patterns and adverse event-related hospitalization among patients with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer after treatment with EGFR tyrosine kinase inhibitor and platinum-based chemotherapy regimens